Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Balkan Med J ; 34(5): 432-435, 2017 Sep 29.
Artículo en Inglés | MEDLINE | ID: mdl-28443576

RESUMEN

BACKGROUND: The causative agent spectrum and resistance patterns of urinary tract infections in children are affected by many factors. AIMS: To demonstrate antibiotic resistance in urinary tract infections and changing ratio in antibiotic resistance by years. STUDY DESIGN: Retrospective cross-sectional study. METHODS: We analysed antibiotic resistance patterns of isolated Gram (-) bacteria during the years 2011-2014 (study period 2) in children with urinary tract infections. We compared these findings with data collected in the same centre in 2001-2003 (study period 1). RESULTS: Four hundred and sixty-five uncomplicated community-acquired Gram (-) urinary tract infections were analysed from 2001-2003 and 400 from 2011-2014. Sixty-one percent of patients were female (1.5 girls : 1 boy). The mean age of children included in the study was 3 years and 9 months. Escherichia coli was the predominant bacteria isolated during both periods of the study (60% in study period 1 and 73% in study period 2). Bacteria other than E. coli demonstrated a higher level of resistance to all of the antimicrobials except trimethoprim-sulfamethoxazole than E. coli bacteria during the years 2011-2014. In our study, we found increasing resistance trends of urinary pathogens for cefixime (from 1% to 15%, p<0.05), amikacin (from 0% to 4%, p<0.05) and ciprofloxacin (from 0% to 3%, p<0.05) between the two periods. Urinary pathogens showed a decreasing trend for nitrofurantoin (from 17% to 7%, p=0.0001). No significant trends were detected for ampicillin (from 69% to 71%), amoxicillin-clavulanate (from 44% to 43%), cefazolin (from 39% to 32%), trimethoprim-sulfamethoxazole (from 32% to 31%), cefuroxime (from 21% to 18%) and ceftriaxone (from 10% to 14%) between the two periods (p>0.05). CONCLUSION: In childhood urinary tract infections, antibiotic resistance should be evaluated periodically and empiric antimicrobial therapy should be decided according to antibiotic sensitivity results.


Asunto(s)
Antibacterianos/farmacología , Pediatría/métodos , Infecciones Urinarias/tratamiento farmacológico , Adolescente , Combinación Amoxicilina-Clavulanato de Potasio/farmacología , Combinación Amoxicilina-Clavulanato de Potasio/uso terapéutico , Ampicilina/farmacología , Ampicilina/uso terapéutico , Antibacterianos/uso terapéutico , Cefazolina/farmacología , Cefazolina/uso terapéutico , Cefixima/farmacología , Cefixima/uso terapéutico , Ceftriaxona/farmacología , Ceftriaxona/uso terapéutico , Cefuroxima/farmacología , Cefuroxima/uso terapéutico , Niño , Preescolar , Ciprofloxacina/farmacología , Ciprofloxacina/uso terapéutico , Infecciones Comunitarias Adquiridas/tratamiento farmacológico , Estudios Transversales , Combinación de Medicamentos , Farmacorresistencia Bacteriana/efectos de los fármacos , Femenino , Bacterias Gramnegativas/efectos de los fármacos , Humanos , Lactante , Masculino , Estudios Retrospectivos , Sulfametizol/farmacología , Sulfametizol/uso terapéutico , Trimetoprim/farmacología , Trimetoprim/uso terapéutico , Turquía , Infecciones Urinarias/microbiología
2.
J Anim Sci ; 81(6): 1456-63, 2003 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-12817493

RESUMEN

The effects of subtherapeutic antimicrobial supplementation and weaning on serum levels of IGF-I and insulin-like growth factor binding proteins (IGFBP)-2, -3 and -4 were determined in crossbred weanling pigs. At weaning, pigs were allotted to a diet containing 21.8% crude protein and 1.15% lysine with or without Aureozol (110 mg/kg of Aureomycin chlortetracycline, 110 mg/kg of sulfathiazole, and 55 mg/kg of penicillin) for 4 wk. Insulin-like growth factor-binding proteins and IGF-I analyses were performed on blood samples that were drawn weekly. Weaning decreased serum IGFBP-3 levels in both control and Aureozol-treated groups on d 6 and d 14 (P < 0.05) relative to preweaning levels. The IGFBP-3 values returned to preweaning levels by d 21. Although the circulating levels of both the 43-kDa and the 39-kDa glycosylation variants of IGFBP-3 were affected by weaning, the level of the 39-kDa IGFBP-3 was affected relatively more than that of the 43-kDa IGFBP-3 (P < 0.05). Compared with circulating IGFBP-3 levels in control pigs, Aureozol-treated pigs had higher circulating IGFBP-3 levels on d 21 (43%, P < 0.05) and d 27 (46%, P < 0.05). In direct contrast to the effect of weaning on serum IGFBP-3 level, serum IGFBP-2 levels increased on d 6 and d 14 after weaning (P < 0.05) and decreased to preweaning levels by d 21. The IGFBP-2 levels continued to decline and were less than preweaning levels by d 27 (P < 0.05). Aureozol treatment had no effect on serum IGFBP-2 levels at any time. Serum levels of nonglycosylated IGFBP-4 were not affected by either weaning or Aureozol supplementation. Weaning decreased circulating IGF-I concentration on d 6 in both control and Aureozol-treated pigs (76 and 73%, respectively, P < 0.05) and on d 14 (62%, P < 0.05) and d 21 (32%, P < 0.05) in control pigs. Aureozol-supplemented pigs had higher serum IGF-I concentrations than control pigs on d 14 (82%, P < 0.05), d 21 (55%, P < 0.05), and d 27 (36%, P < 0.05). The Aureozol-fed pigs had a 14.2% increase in BW gain (P < 0.05) and a 59.6% increase in ADG (P < 0.05) compared with pigs fed the control diet. Both Aureozol-supplementation and weaning cause changes in serum IGFBP levels and IGF-I concentrations that might be involved in regulating rate and efficiency of growth.


Asunto(s)
Antiinfecciosos/farmacología , Proteínas de Unión a Factor de Crecimiento Similar a la Insulina/sangre , Factor I del Crecimiento Similar a la Insulina/metabolismo , Porcinos/sangre , Destete , Alimentación Animal , Animales , Antiinfecciosos/administración & dosificación , Clortetraciclina/administración & dosificación , Clortetraciclina/farmacología , Relación Dosis-Respuesta a Droga , Femenino , Proteína 1 de Unión a Factor de Crecimiento Similar a la Insulina/sangre , Proteína 2 de Unión a Factor de Crecimiento Similar a la Insulina/sangre , Proteína 3 de Unión a Factor de Crecimiento Similar a la Insulina/sangre , Masculino , Penicilinas/administración & dosificación , Penicilinas/farmacología , Distribución Aleatoria , Sulfametizol/administración & dosificación , Sulfametizol/farmacología , Porcinos/crecimiento & desarrollo , Aumento de Peso/efectos de los fármacos
3.
Methods Find Exp Clin Pharmacol ; 6(12): 731-5, 1984 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-6241648

RESUMEN

Systemic bacterial infections due to Escherichia coli MB 2884, Proteus mirabilis MB 3125 and Klebsiella pneumoniae MB 4005 were well controlled by treatment with norfloxacin both in normal and streptozotocin-induced diabetic mice. similar observations were made when trimethoprim-sulfamethoxazole was used against susceptible pathogens. Systemic infection due to Pseudomonas aeruginosa MB 4700 was well controlled by norfloxacin and gentamicin in normal mice; this infection was more refractory to treatment by both drugs in diabetic animals. These observations suggest that norfloxacin may be an effective drug in the treatment of bacterial infections which may occur under diabetic conditions, and further investigation is warranted.


Asunto(s)
Antibacterianos/uso terapéutico , Infecciones Bacterianas/tratamiento farmacológico , Diabetes Mellitus Experimental/complicaciones , Gentamicinas/uso terapéutico , Ácido Nalidíxico/análogos & derivados , Sulfametizol/uso terapéutico , Sulfatiazoles/uso terapéutico , Trimetoprim/uso terapéutico , Animales , Antibacterianos/farmacología , Bacterias/efectos de los fármacos , Combinación de Medicamentos/farmacología , Combinación de Medicamentos/uso terapéutico , Evaluación Preclínica de Medicamentos , Farmacorresistencia Microbiana , Femenino , Gentamicinas/farmacología , Ratones , Ácido Nalidíxico/farmacología , Ácido Nalidíxico/uso terapéutico , Norfloxacino , Sulfametizol/farmacología , Trimetoprim/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA